Summit Therapeutics

Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Xconomy
Summit Therapeutics
ezutromid
clinical trials
Duchenne Muscular Dystrophy
Flag link:
Data from trials could send these clinical-stage biotech stocks soaring or crashing
Data from trials could send these clinical-stage biotech stocks soaring or crashing
Motley Fool
clinical trials
biotech
Summit Therapeutics
DMD
Jounce Therapeutics
JTX-2011
TG Therapeutics
ublituximab
Flag link:
How the newest Duchenne biotechs are getting a boost from patient groups
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
Flag link:
Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
Yahoo/Benzinga
Sarepta Therapeutics
Europe
Duchenne Muscular Dystrophy
Summit Therapeutics
ezutromid
Flag link:
Sarepta: The Competition Is At The Gate
Sarepta: The Competition Is At The Gate
Seeking Alpha
Sarepta Therapeutics
eteplirsen
Biomarin
Summit Therapeutics
PTC Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Summit develops a unique Duchenne drug for any gene mutation
Summit develops a unique Duchenne drug for any gene mutation
Bizjournals.com
Summit Therapeutics
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Summit pulls off a downsized IPO for its DMD drug
Summit pulls off a downsized IPO for its DMD drug
Fierce Biotech
Duchenne Muscular Dystrophy
Summit Therapeutics
SMT C1100
IPOs
Flag link: